Form D · Biotechnology
Novalent Biotech, Inc.
Greensboro, NC · CIK 0001895518
Offering snapshot reported Nov 29, 2021 · SEC filing
- Reported sold
- $11M Offering amount: $11M
- Investors reported
- 712 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Oct 21, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 29, 2021 | Initial | $11,000,000 | No comparison | 712 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $990K
- Finders' fees
- $0
- Form D file number
- 021-422700
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| OpenDeal Broker LLC | 297797 |
Source: Form D, filed Nov 29, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bill Massa | Director, Executive |
| Alex Ovchar | Director, Executive |
| Kevin Parrish | Director, Executive |
| Wayne Thompson | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2319 Joe Brown Dr.
Greensboro, NC, 27405
Greensboro, NC, 27405